Product Information
DELSTRIGO 100-300-300 MG TAB is a brand product labeled by Merck Sharp & Dohme LLC, priced at $93.0607 per EA under NDC 00006500701. Its NADAC has been published 168 times since Jul 19, 2023.
FDA first approved this application on Aug 30, 2018.
Strength
100; 300; 300 mg/1; mg/1; mg/1
Manufacturer
Merck Sharp & Dohme LLCNDC
00006500701
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATEApproval Type
New Drug (NDA)
FDA Application
NDA210807FDA Approved
8/30/2018
On Market Since
7/20/2018
Pharmacological Classes
Price Statistics
The NADAC for DELSTRIGO 100-300-300 MG TAB has been published 168 times since Jul 19, 2023, and over the history we have for it it has risen 12.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $93.0607 per EA |
|---|---|
| All-time high | $93.0607 (Sep 30, 2026) |
| All-time low | $82.6907 (Jul 19, 2023) |
| 52-week high | $93.0607 |
| 52-week low | $90.6516 |
| Median price | $90.4873 |
| Average price | $88.6874 |
| Largest weekly change | +5.0% (Jan 17, 2024) |
| Weeks tracked | 168 |
| Tracking since | Jul 19, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the doravirine, lamivudine, and tenofovir disoproxil fumarate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Merck Sharp & Dohme LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
doravirine, lamivudine, and tenofovir disoproxil fumarate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DELSTRIGO 100-300-300 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for DELSTRIGO 100-300-300 MG TAB, manufactured by Merck Sharp & Dohme LLC, is $93.0607 per EA (NDC 00006500701), effective Sep 30, 2026.
How has the price of DELSTRIGO 100-300-300 MG TAB changed over time?
Over the history we have for it, the NADAC for DELSTRIGO 100-300-300 MG TAB has risen 12.5%. It has been tracked across 168 weekly CMS publications since Jul 19, 2023.
What are the highest and lowest recorded NADAC prices for DELSTRIGO 100-300-300 MG TAB?
Since Jul 19, 2023, the NADAC for DELSTRIGO 100-300-300 MG TAB has ranged from a low of $82.6907 (Jul 19, 2023) to a high of $93.0607 (Sep 30, 2026), with a median of $90.4873 per EA.
Are there cheaper alternatives to DELSTRIGO 100-300-300 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of DELSTRIGO 100-300-300 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DELSTRIGO 100-300-300 MG TAB?
DELSTRIGO 100-300-300 MG TAB (NDC 00006500701) is labeled by Merck Sharp & Dohme LLC, and CMS classifies it as a brand product.